10-Jul-2026
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Wed, 8-Jul 4:05 PM ET)
Candel Therapeutics Awards Inducement Options as Clinical Pipeline Gains FDA Momentum
Market Chameleon (Thu, 2-Jul 5:18 AM ET)
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Wed, 1-Jul 4:05 PM ET)
Globe Newswire (Tue, 30-Jun 8:05 AM ET)
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
Globe Newswire (Thu, 25-Jun 8:05 AM ET)
Globe Newswire (Tue, 2-Jun 8:05 AM ET)
Globe Newswire (Fri, 15-May 4:05 PM ET)
Market Chameleon (Thu, 14-May 6:26 AM ET)
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Globe Newswire (Thu, 14-May 8:05 AM ET)
Candel Therapeutics to Present at Upcoming Investor Conferences
Globe Newswire (Wed, 13-May 8:05 AM ET)
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Candel Therapeutics trades on the NASDAQ stock market under the symbol CADL.
As of July 10, 2026, CADL stock price declined to $9.49 with 1,144,753 million shares trading.
CADL has a beta of 1.02, meaning it tends to be more sensitive to market movements. CADL has a correlation of 0.03 to the broad based SPY ETF.
CADL has a market cap of $695.11 million. This is considered a Small Cap stock.
In the last 3 years, CADL traded as high as $14.60 and as low as $.66.
The top ETF exchange traded funds that CADL belongs to (by Net Assets): XBI, IWM, VTI, IWO, IBB.
CADL has outperformed the market in the last year with a return of +54.3%, while the SPY ETF gained +21.8%. In the last 3 month period, CADL beat the market returning +96.5%, while SPY returned +11.4%. However, in the most recent 2 weeks CADL has underperformed the stock market by returning -3.1%, while SPY returned +3.6%.
CADL support price is $9.45 and resistance is $10.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CADL shares will trade within this expected range on the day.